Purdue Pharma , the manufacturer of controversial opioid OxyContin , is reportedly facing financial difficulties , with revenue expected to fall below $ 1bn in 2019 for the first time in 10 years . Contraction of the workforce , falling sales , and a pending bankruptcy filing , as well as potential restructuring and opioid - related lawsuits across the US , are among the challenges faced by the company . Purdue , which is controlled by the Sackler family , is also thought to be facing a government investigation into fraud at affiliated hospitals . The pharmaceutical 's core product , prescription painkiller OxyContin , is the subject of numerous lawsuits and is experiencing reduced sales .
Purdue Pharma, the producer of controversial opioid OxyContin, is reportedly facing financial challenges, with revenue expected to fall below $1bn in 2019 for the first time in 10 years. Contraction of the workforce, falling sales, and a mooted bankruptcy filing, as well as potential restructuring and opioid-related lawsuits across the US, are among the challenges faced by the company. Purdue, which is controlled by the Sackler family, is also thought to be facing a government investigation into fraud at affiliated entities. The pharmaceutical's core product, prescription painkiller OxyContin, is the subject of numerous lawsuits and is experiencing reduced sales.